VIDEO from Novartis Available on thenewsmarket.com: Novartis Presents Data about Tasigna in Treatment of Patients with Newly Dia

NEW YORK, Dec. 6, 2010 /PRNewswire/ -- See video from Novartis at:

http://www.thenewsmarket.com/Releases/StoryDetailPage.aspx?GUID=b76c2552-3cd3-4727-8f46-ef825bcb66d4#

Novartis announced 24-month data showing that Tasigna® (nilotinib) continues to surpass Glivec® (imatinib)* in the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase1. These new data, from the first Phase III comparison of the two oral therapies as initial treatment for this blood cancer, were presented at the 52nd Annual Meeting and Exposition of the American Society of Hematology (ASH) in Orlando, Florida. Available video includes an edited package, product shots and soundbites.

About thenewsmarket.com

thenewsmarket.com delivers free broadcast- and streaming-quality video and multimedia content directly to media around the world, 24/7. More than 25,000 media outlets in 190+ countries use thenewsmarket.com, including the AP, BBC, CNBC, CNN, France 24, N24, nytimes.com, RAI, TVE, ZDF and a lot more.  

Registered journalists can preview and download video, audio, text, graphics and photos at http://www.thenewsmarket.com.

If not already registered, please take a moment to sign up - registration is quick, easy and free: http://www.thenewsmarket.com/registration

We are always happy to receive your feedback, suggestions or enquiries.  Email us at [email protected]

Story Id: 20823

SOURCE thenewsmarket.com

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.